Dramatically improveobstructive sleep apnea (OSA)therapy adherence

Predict and prevent to improve adherance

Our groundbreaking AI algorithms have been designed to deliver lower, more comfortable air pressures. This leads to an improvement in comfort and adherence on conventional CPAP machines. Building on cMAP®’s proprietary technology, we are also creating the groundwork to build the next generation of battery-enabled, wearable CPAPs.

Tested in clinical studies

cMAP® is being developed based on tens of thousands of apneas collected from in-home patient’s CPAP machines. cMAP® has been validated in a first-in-human trial on current CPAPs in a double-blinded sleep lab study at the QEII hospital in Halifax, Canada.

In a clinical trial, cMAP® proved to:

Predict respiratory failure in advance of an apnea occurring

Predict the type of upcoming apnea (OSA, CSA and hypopnea)

Result in a statistically significant drop in AHI

Lower respiratory effort-related arousals (RERAs)

Lower a patient’s Non-REM heart rate

*Citation: https://pubmed.ncbi.nlm.nih.gov/37030831/

Clinical validation:

2019-2020

Observational Study

Completed

Data collection from CPAP patients:

Proof of prediction of apneas
Health Canada Approval #296175

2021-2022

First-in-Human Study

Completed

Deploying cMAP® on real patients:

Proof of prevention of apneas
Health Canada Approval #329649

2023

Home-Patient Improvements

Completed

Transformed cMAP^® into a stand-alone algorithm

2024

Comfort Study

Completed

Low-Pressure therapy without compromising AHI
Health Canada Approval #368865

2024-25

Adherence Study

In Progress

Adherence to cMAP^® vs APAP in naïve patients

Aligned incentives that
benefit all stakeholders

Manufacturer

Revenue increase for manufacturers due to greater initial acceptance and continued patient use of CPAP machines
Every 5 years new device (device sales)
Increase consumable resupply purchases as more patients use their CPAP machines and for more of the machine’s useful life
Potential for Reduced COGS and greater margins because cMAP® technology leads to smaller more compact devices without loss of efficacy.

DME

Increased revenue for Durable Medical Equipment suppliers (DMEs) due to increased sales of machines and consumable resupply
Reduction in labor cost for DMEs because more comfortable use leads to less required patient support

Patient

QoL increases
Reduction of co-morbid conditions associated with untreated OSA (heart disease¹, diabetes², stoke³^,⁴ etc.)
12+ months are lifetime users

Dramatically improve
obstructive sleep apnea (OSA)
therapy adherence

cMAP® is a patented software which has been designed to be compatible with any Positive Airway Pressure (PAP) machine, including CPAPs

Predict and prevent to improve adherance

“cMAP® enables you to adhere to it — and benefit from the outcome.”

Tested in clinical studies

In a clinical trial, cMAP® proved to:

Clinical validation:

Aligned incentives that
benefit all stakeholders

Want to learn more?

cMAP® is a patented software which has been designed to be compatible with any Positive Airway Pressure (PAP) machine, including CPAPs

Predict and prevent to improve adherance

“cMAP® enables you to adhere to it — and benefit from the outcome.”

Tested in clinical studies

In a clinical trial, cMAP® proved to:

Clinical validation:

Aligned incentives that benefit all stakeholders

Want to learn more?

Aligned incentives that
benefit all stakeholders